Maxim Group analyst Naz Rahman maintained a Buy rating on Virpax Pharmaceuticals (VRPX – Research Report) yesterday and set a price target of $4.00. The company’s shares opened today at $0.83.
Rahman covers the Healthcare sector, focusing on stocks such as Clene, Quoin Pharmaceuticals, and scPharmaceuticals. According to TipRanks, Rahman has an average return of 4.0% and a 36.07% success rate on recommended stocks.
Virpax Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
See the top stocks recommended by analysts >>
Based on Virpax Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $1.52 million. In comparison, last year the company had a GAAP net loss of $5.14 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Virpax Pharmaceuticals Inc is a preclinical-stage pharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management.
Read More on VRPX:
